Paysign Inc. Q3 2026 Earnings Call - PAYSIGN INC

Financial Performance:

• Total revenue grew 43% year-over-year (YoY) to $30.8 million in Q3 2026.
• Patient affordability revenue doubled to $16.6 million (up 110% YoY), while plasma revenue grew 7.5% to $13.8 million.
• Net income surged over 200% to $6.7 million ($0.11 per diluted share) compared to $2.2 million in Q3 2025.
• Gross margins expanded 840 basis points to 64.7% due to higher-mix revenue from patient affordability.
• Operating margin tripled to 23.8% (up from 7.3% YoY) with operating leverage converting over $0.60 of every incremental revenue dollar to adjusted operating income.
• Adjusted EBITDA increased 118% to $11 million, with an adjusted EBITDA margin of 35.7%.
• Balance sheet remains strong with $34.5 million in unrestricted cash and zero bank debt; restricted cash rose to $201.8 million driven by program deposits.

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $114 million–$117 million (exceeding prior guidance).
• Updated net income guidance to $23 million–$24 million ($0.37–$0.38 per share) and adjusted EBITDA to $38.5 million–$40 million.
• Full-year gross margin guidance set at 63.5%–64.5%, supported by the growing patient affordability mix.
• Expected to end the year with 190–195 active patient affordability programs and 445–450 plasma centers.
• Q4 outlook includes a $1.5 million revenue and $700,000 gross profit reduction due to the loss of 113 plasma centers to a competitor.
• Management anticipates program ramp-ups in H2, with 2027 growth supported by a robust pipeline and expected FDA approval for the Aferion software.

Business Segments and Product Lines:

• Patient Affordability: Driven by 19 new programs launched in Q3 (167 active total); revenue per program increased 32% to $99,524; delivered $367 million in patient assistance in Q3 and $3.2 billion cumulatively since launch.
• Plasma: Serves 562 centers with 14.9% growth in average monthly revenue per center ($8,187); facing a temporary consolidation loss of 113 centers expected to be offset by new center acquisitions in 2027.
• Aferion: A plasma-specific software suite currently under FDA regulatory review; completed in-center testing and submitted results; generating strong interest in US and EU markets.
• Dynamic Business Rules (DBR): Insulated pharmaceutical clients from $82.5 million in costs in Q3 alone, with $553 million year-to-date, driving client stickiness and margin expansion.

Market and Competitive Landscape:

• Patient affordability market showing strong utilization and deepening client relationships; value proposition reinforced by industry trends against copay maximizers and accumulators.
• Plasma market described as mature with limited organic growth, necessitating the shift toward higher-margin, durable value-added services.
• Competitive dynamics in plasma involve banking partnerships; a key customer consolidated with an existing bank partner, resulting in the transition of 113 centers, though management views this as an industry norm.
• Expansion efforts targeting collection companies not currently using Paysign in the plasma space and developing a European base for Aferion via Dublin subsidiary.

Risks and Challenges:

• Regulatory uncertainty regarding the FDA approval timeline for the Aferion donor management system; no confirmed launch date available.
• Revenue headwinds in Q4 due to the migration of 113 plasma centers to a competitor, though management expects this loss to be temporary and replaceable.
• Seasonality in claims volume (typically lower in Q3/Q4) is currently masked by program onboarding growth; future seasonality may re-emerge if program growth slows.
• Stock-based compensation and discrete tax adjustments contributed to a higher effective tax rate of 17.8% in Q3 compared to 1.4% in the prior year.

Management Commentary and Tone:

• Management expressed high confidence in the strategic pivot, citing the "engine" of patient affordability as the primary driver of growth and margin expansion.
• Tone remained optimistic despite the plasma center transition, emphasizing the durability of the business model and the "sticky" nature of pharmaceutical client relationships.
• Executives highlighted the successful execution of a hybrid model combining cash-generative plasma services with high-margin, scalable patient affordability solutions.
• CEO Mark Newcomer and CFO Jeff Baker reiterated that the company is well-positioned to deliver consistent top- and bottom-line growth in the foreseeable future.

Analyst Questions and Answers:

• Plasma Replacement: Analysts asked if the lost 113 centers could be replaced; management confirmed sufficient market opportunities exist and active discussions are underway, though timing of transitions varies.
• Expense Structure: Regarding cost reductions from lost plasma centers, management noted the variable cost model aligns expenses with revenue, limiting immediate SG&A savings but maintaining long-term margin health.
• Pharma Seasonality: Clarified that Q3 performance masked traditional seasonality due to aggressive program onboarding; most program launches historically occur in H2 and early Q1 to align with insurance plan resets on January 1st.
• Cross-Sell Opportunities: Management indicated a unified tech stack serves three verticals (medical benefit, specialty pharma, retail pharma), allowing for efficient cross-selling of products like portals and BI tools.
• Aferion Adoption: Expressed confidence that interest in Aferion remains high in the US and EU, anticipating a rapid ramp-up in book of business once regulatory approval is secured.

Other Key Points:

• Paysign highlighted the cumulative $3.2 billion in financial assistance delivered to patients since the platform's inception, framing their mission around patient outcomes alongside commercial value.
• The company will attend the Informa Co-Pay Congress in November to showcase new service offerings for 2027.
• The strategic narrative focuses on leveraging existing infrastructure to move from a transactional payment processor to a value-added software and affordability partner.
• Management confirmed the Q3 results were driven by better-than-expected utilization and program scaling, rather than just new additions.